Business
MannKind Announces Ralinepag Dry Powder Inhalation (DPI) Program to be Pursued for Pulmonary Hypertension and Fibrotic Lung Diseases
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPIUnited Therapeutics plans to be the primary manufacturer of ralinepag DPIMannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD),
About this update from Mannkind Corporation
[{"type":"image","alt":"MannKind","displaySize":"","headline":null,"caption":"MannKind","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":157,"url":"https://media.zenfs.com/en/globenewswire.com/25877a202ba02abe901e1a60c89ab7e1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rnJ2dlyjbOeUw2hiS_KryQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyMA--/https://media.zenfs.com/en/globenewswire.com/25877a202ba02abe901e1a60c89ab7e1","width":300,"height":157}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"The formulation is being developed in collaboration with United Therapeutics Corporation ","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"United Therapeutics made an additional $5 million payment to MannKind to support the rapid advancement of ralinepag DPI","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"United Therapeutics plans to be the primary manufacturer of ralinepag DPI","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"MannKind eligible to receive up to $35 million in development milestones plus 10% royalties on net sales","length":104,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":384,"olType":false},{"type":"text","content":"DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products, today announced that it has been developing a dry powder inhalation (DPI) formulation of ralinepag, known as ralinepag DPI (MNKD-1501), for United Therapeutics Corporation (Nasdaq: UTHR), under the companies’ expanded license and collaboration agreement announcement from August 2025.","length":491,"tagName":"p"},{"type":"text","content":"Ralinepag is an investigational prostacyclin receptor agonist that exhibits a long half-life and high potency in the pulmonary vasculature. In March 2026, United Therapeutics reported that its long-term pivotal phase 3 ADVANCE OUTCOMES study of ralinepag extended-release tablets in pulmonary arterial hypertension (PAH) met its primary endpoint with high statistical significance.","length":381,"tagName":"p"},{"type":"text","content":"“Supported by the strength of the pivotal ADVANCE OUTCOMES results, we believe ralinepag has the potential to redefine the PAH treatment landscap...